EMEA-002058-PIP01-16-M01 - paediatric investigation plan

Entospletinib

Key facts

• Active Substance:
  Entospletinib
• Therapeutic area:
  Oncology
• Decision number:
  P/0518/2022
• PIP number:
  EMEA-002058-PIP01-16-M01
• Pharmaceutical form(s):
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
• Condition(s) / indication(s):
  Treatment of acute myeloid leukaemia
• Route(s) of administration:
  • Oral use
  • Gastric use
• Contact for public enquiries:

  Kronos Bio Inc.

  email: [e-mail]; tel: [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  30/12/2022

Decision

P/0518/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for entospletinib (EMEA- 002058-PIP01-16-M01)

AdoptedReference Number: EMA/912437/2022